Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 12:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 403 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: aldesleukin Clear all
Withdrawn Phase 1Phase 2 Interventional

CISH Inactivated TILs in the Treatment of NSCLC

NCT05566223
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Large Cell Lung Cancer
Interventions
Fludarabine, Cyclophosphamide, CISH Inactivated TIL, Aldesleukin, Pembrolizumab
Drug · Biological
Lead sponsor
Intima Bioscience, Inc.
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Duarte, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 1, 2026, 12:10 PM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia

NCT00002925
View directory record Official record
Conditions
Leukemia
Interventions
ara-C, Daunorubicin, Etoposide, PSC-833, Aldesleukin
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years to 59 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
33
States / cities
La Jolla, California • San Francisco, California • Wilmington, Delaware + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2012 · Synced Sep 1, 2026, 12:10 PM EDT
Terminated Phase 1 Interventional

Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors

NCT01081808
View directory record Official record
Conditions
Neoplasms, Tumors, Solid Tumors, Metastatic Cancer
Interventions
EGFRBi-armed autologous activated T cells
Biological
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 1, 2026, 12:10 PM EDT
Terminated Phase 2 Interventional Results available

Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma

NCT01754376
View directory record Official record
Conditions
Melanoma
Interventions
Aldesleukin, Vemurafenib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 1, 2026, 12:10 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

NCT00126490
View directory record Official record
Conditions
Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Interventions
Aldesleukin, Bevacizumab, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Sep 1, 2026, 12:10 PM EDT
Terminated Phase 1 Interventional

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

NCT04551885
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
FT516, Avelumab, Cyclophosphamide, Fludarabine, IL-2
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Minneapolis, Minnesota • Hackensack, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 1, 2026, 12:10 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients With CD4 Counts Greater Than 300 Cells/mm3

NCT00000949
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
15
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 1, 2026, 12:10 PM EDT
Completed Phase 1 Interventional

Interleukin-2 in Treating Patients With Myelodysplastic Syndrome

NCT00002746
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
aldesleukin
Biological
Lead sponsor
University of Washington
Other
Eligibility
15 Years to 120 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Sep 1, 2026, 12:10 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer

NCT01160445
View directory record Official record
Conditions
Metastatic Melanoma, Metastatic Renal Cancer
Interventions
Zanolimumab, Aldesleukin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Sep 1, 2026, 12:10 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes

NCT01273181
View directory record Official record
Conditions
Metastatic Cancer, Metastatic Renal Cancer, Metastatic Melanoma
Interventions
PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes, Aldesleukin, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Sep 1, 2026, 12:10 PM EDT
Completed Phase 1 Interventional Results available

Low Dose IL-2 for Ulcerative Colitis

NCT02200445
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Interleukin-2 (aldesleukin).
Drug
Lead sponsor
Scott B. Snapper, MD PHD
Other
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 1, 2026, 12:10 PM EDT
Completed Phase 1 Interventional

Phase I Trial of the Combination of Zidovudine and Recombinant Interleukin-2 in Patients With Persistent Generalized Lymphadenopathy

NCT00000728
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 1, 2026, 12:10 PM EDT
Active, not recruiting Phase 2 Interventional

High Dose IL 2 and Entinostat in RCC

NCT03501381
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Entinostat, Interleukin-2
Drug
Lead sponsor
Roberto Pili
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Sep 1, 2026, 12:10 PM EDT
Completed Phase 1 Interventional

Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2

NCT01082926
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Brain Stem Glioma, Ependymoblastoma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Grade III Meningioma, Meningeal Hemangiopericytoma, Mixed Glioma, Pineal Gland Astrocytoma, Brain Tumor
Interventions
therapeutic allogeneic lymphocytes, aldesleukin, laboratory biomarker analysis, positron emission tomography
Biological · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 1, 2026, 12:10 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD

NCT02340676
View directory record Official record
Conditions
Chronic Graft-versus-host-disease
Interventions
Extracorporeal Photopheresis (ECP), Interleukin-2
Procedure · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 1, 2026, 12:10 PM EDT
Completed Early Phase 1 Interventional

Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer

NCT00276835
View directory record Official record
Conditions
Kidney Cancer, Melanoma (Skin)
Interventions
High-dose interleukin-2, genistein
Biological · Dietary Supplement
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Sep 1, 2026, 12:10 PM EDT
Completed Phase 1Phase 2 Interventional

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer

NCT00019591
View directory record Official record
Conditions
Colorectal Cancer
Interventions
aldesleukin, ras peptide cancer vaccine, adjuvant therapy
Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
2
States / cities
Bethesda, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Sep 1, 2026, 12:10 PM EDT
Completed Phase 1 Interventional

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

NCT03841110
View directory record Official record
Conditions
Advanced Solid Tumors, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small Cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma
Interventions
FT500, Nivolumab, Pembrolizumab, Atezolizumab, Cyclophosphamide, Fludarabine, IL-2
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
San Diego, California • Minneapolis, Minnesota • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2023 · Synced Sep 1, 2026, 12:10 PM EDT
Terminated Phase 1 Interventional

IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma

NCT01409174
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Temozolomide, Cisplatin, Interferon Alfa-2b, Interleukin-2
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 1, 2026, 12:10 PM EDT
Terminated Phase 2 Interventional Results available

Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML

NCT00871689
View directory record Official record
Conditions
Leukemia
Interventions
aldesleukin, cyclophosphamide, fludarabine phosphate, umbilical cord blood transplantation, total-body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 45 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Sep 1, 2026, 12:10 PM EDT
Not listed Phase 1Phase 2 Interventional

Biological Therapy in Treating Women With Metastatic Breast Cancer

NCT00002780
View directory record Official record
Conditions
Breast Cancer
Interventions
aldesleukin, cytokine therapy, sargramostim, carboplatin, cyclophosphamide, thiotepa, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
St. Luke's Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 1, 2026, 12:10 PM EDT
Completed Phase 1 Interventional

Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant

NCT00107354
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
aldesleukin, therapeutic allogeneic lymphocytes, therapeutic autologous lymphocytes, cytarabine, etoposide, mitoxantrone hydrochloride, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
14 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 19, 2010 · Synced Sep 1, 2026, 12:10 PM EDT
Completed Phase 2 Interventional Results available

Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma

NCT01659151
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
High Dose Interleukin-2 (IL-2), ACT with TIL Infusion, Vemurafenib, Lymphodepletion
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 1, 2026, 12:10 PM EDT
Active, not recruiting Phase 1 Interventional

Aerosolized Aldesleukin in Treating Patients With Lung Metastases

NCT01590069
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma, Metastatic Osteosarcoma, Metastatic Renal Cell Cancer, Sarcoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Osteosarcoma AJCC v7, Stage IV Renal Cell Cancer AJCC v7
Interventions
Aerosolized Aldesleukin, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 1, 2026, 12:10 PM EDT